MyCME, the leader in free medical education, offers a host of courses across all infectious diseases. Access the entire library of Infectious Diseases CME and CE for Free.
The top infectious disease CME courses available right now on www.myCME.com featuring courses on hepatitis, COVID-19, Ebola, and more.
Program Description
Listen in as two patients share their experiences with treatment for C. difficile and its recurrence. In this short webisode Dr. Paul Feuerstadt and Dr. Sahil Khanna discusses fresh insights and strategies for selecting treatment of CDI in real-world settings.
Educational Objectives
Upon completion, participants will be able to:
- Discuss the selection of antimicrobials considerate of their impact on gut microbiota
- Assess available and updated clinical guidelines to ensure evidence-based therapeutic selection for treatment of initial infection and prevention of recurrent CDI
- Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
intended audience
This activity is intended for gastroenterologists, infectious disease specialists, primary care physicians, advanced practice providers and other clinicians who care for patients with initial and recurrent Clostridioides difficile infection.
Commercial supporters
Supported by an educational grant from Merck & Co., Inc
Max credits:
- 0.75 / AMA PRA Category 1 Credits
expires: May 9, 2023
Program Description
Basic infection prevention and control concepts are lacking in behavioral health facilities, and many do not have trained Infection Preventionists. This training covers basic concepts, including environment of care, to promote a successful infection prevention program in behavioral health settings.
Education Objectives
Upon conclusion, participants should be better able to:
- Determine the basic components of an Infection Prevention Program in a behavioral health setting
- Improve compliance with infection prevention practices
- Engage health care workers, physicians, and leaders
- Manage time for infection prevention activities
- Create an Infection Prevention Program
intended audience
Physicians, Nurse Practitioners, Physician Assistants, Pharmacists, Long-Term Care Clinicians, Emergency Medicine clinicians, and any other specialty where clinicians need to understand infection prevention and control
Commercial supporters
Commercial support was not received for this activity.
Max credits:
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / AAPA Category 1 CME Credit
- 1.00 / ANCC Contact Hour
- 1.00 / CE for Pharmacists
expires: June 30, 2025
Program Description
Current treatments for the outpatient treatment of COVID-19 have garnered much attention in the medical community and the broader media. Many treatments are not supported by available evidence or carry a risk profile that may not warrant their use. Given the difficulty in outpatient administration of IV or subcutaneous monoclonal antibodies, researchers have been working towards the oral treatment of COVID-19. Several candidates are in late-stage clinical trials, with some emerging clinical data. As such, providers require an educational program that broadly encompasses the testing and treatment of COVID-19, so they will be able to properly counsel patients.
Educational Objectives
Upon completion, participants should be able to:
- Apply understanding of COVID-19 testing methods to patient counseling and treatment choices.
- Incorporate knowledge of currently authorized/approved and recommended COVID-19 treatments to the outpatient management of patients with COVID-19.
- Use knowledge of emerging COVID-19 treatments to better counsel and manage affected patients.
intended audience
This program is designed to meet the educational needs of clinicians treating patients with COVID-19 infection.
Commercial supporters
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Max credits:
- 1.50 / AMA PRA Category 1 Credit(s)
- 1.50 / AAPA Category 1 CME Credits
expires: September 1, 2023
Program Description
This plot-your-own-course activity will focus on evidence/guidelines for ART optimization in treatment-experienced patients with HIV and provides an overview of emerging antiretrovirals (ARVs).
Educational Objectives
Upon completion, participants should be able to:
- Apply recommended strategies to increase competency in incorporating a comprehensive sexual history and risk assessment into initial and routine patient visits
- Select ART regimens that minimize drug-drug interactions and toxicities, support adherence, and consider patient and systemic factors including patient preference
- Summarize new paradigms and approaches to treating and managing HIV, including potential two-drug ARV combinations
intended audience
This educational activity has been designed to meet the needs of US-based HIV specialty clinicians and infectious disease physicians involved in managing care for patients who are at risk for or living with HIV.
Commercial supporters
This activity is supported by an educational grant from Gilead Sciences, Inc.
Max credits:
- 0.75 / AMA PRA Category 1 Credit
Expires: June 21, 2023
Program Description
Olfactory dysfunction is associated with significantly increased risk of mortality and has a substantial negative impact on quality of life. This program provides an overview of the management strategies and treatment options for COVID-19–related loss of smell and other postviral forms of olfactory dysfunction.
Educational Objectives
Upon completion, learners will be better able to:
- Identify the presentation of olfactory loss and dysfunction
- Discuss the treatment options and management strategies for people with olfactory loss or dysfunction
intended audience
Allergists/Immunologists, Infectious Disease Specialists, Internal Medicine, Family Physicians, NPs and PAs
Commercial supporters
This activity is not commercially supported.
Max credits:
- 0.75 / AMA PRA Category 1 Credit
- 0.75 / ANCC Contact Hour
expires: July 29, 2024
Program Description
In January 2022, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) updated and simplified guidelines for the administration of pneumococcal vaccination in adults at risk of pneumococcal infection. dr Julio Ramirez and Dr. Ruth Carrico of the Norton Infectious Diseases Institute in Louisville, KY, discusses these updated guidelines and the importance of pneumococcal vaccination in at-risk adults.
Educational Objectives
At the conclusion of this activity, participants should be better able to:
- Discuss the scope, burden, and risks of pneumococcal disease in adults, including special populations such as the elderly and the immunocompromised
- Describe the different types of available pneumococcal vaccines, including their characteristics and logistics for use
- Outline the newly updated ACIP recommendations for pneumococcal vaccination in adults
intended audience
Infectious Disease Specialists, Internal Medicine, Family Practice, Geriatric Clinicians, NPs, PAs, and Pharmacists
Commercial supporters
Supported by an educational grant from Pfizer Inc.
Max credits:
- 1.00 / AMA PRA Category 1 Credit(s)
- 1.00 / CE for Pharmacists
expires: September 15, 2023
Program Description
This educational activity is designed to review the differences between egg-based inactivated, cell culture-based inactivated, and live attenuated influenza vaccines in the pediatric population; and the real-world clinical findings regarding the efficacy of pediatric influenza vaccines and how immunization rates can be improved.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Recognize the differences between, and applications for, egg-based inactivated, cell culture-based inactivated, and live attenuated influenza vaccines in the pediatric population.
- Examine real-world clinical findings regarding the efficacy of pediatric influenza vaccines and how immunization rates can be improved, including strategies to encourage patient adherence and follow-ups.
intended audience
The intended audience for this activity is pediatric nurse practitioners, pediatric physician assistants and other health care professionals involved in the management of pediatric patients with influenza.
Commercial supporters
This activity is supported by an educational grant from Seqirus USA Inc.
Max credits:
- 0.75 / AAPA Category 1 CME Credits
- 0.75 / ANCC Contact Hours
- 0.75 / AANP Contact Hours
expires: October 30, 2023
Program Description
This CMEO BriefCase will introduce a case involving the incorporation of routine surveillance for HCC in a patient with HCV. Join our faculty experts as they delve into the epidemiology and shared pathobiology of HCV and decompensated cirrhosis, identify compensated versus decompensated cirrhosis, and discuss surveillance strategies for HCC.
Educational Objectives
Upon completion, participants should be able to:
- Integrate routine surveillance for HCC into clinical follow-up for patients with HCV.
intended audience
US and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care
Commercial supporters
Supported by an educational grant from Gilead Sciences, Inc.
Max credits:
- 0.50 / AMA PRA Category 1 Credit(s)
- 0.50 / AMA PRA Category 1 Credit(s) / ABIM MOC Point(s)
- 0.50 / AAPA Category 1 CME Credits
- 0.50 / ANCC Contact Hour(s)
- 0.50 / CE for Pharmacists
expires: May 17, 2023
Program Description
Two fundamental misunderstandings, that CAP is both acute and localized, have led to misconceptions about its prognosis and treatment. It is crucial for clinicians to understand that pneumonia can affect multiple organ systems and have long-term consequences.
Educational Objectives
Upon completion, participants should be better able to:
- Describe pneumonia pathogenesis
- Recognize the types of organ dysfunction associated with pneumonia
- Identify post-acute sequelae of pneumonia
intended audience
This activity is intended for Pulmonologists and Primary Care, MDs, NPs and PAs
Commercial supporters
This activity is not commercially supported.
Max credits:
- 0.50 / AMA PRA Category 1 Credit(s)
expires: June 15, 2023
Program Description
This CMEO BriefCase will introduce a complex case involving treatment and management considerations for a patient with HIV and HCV. Join Drs. Nancy Reau and Christian Ramers as they explore the epidemiology and shared pathobiology of liver fibrosis in HIV/HCV, real-world data for available therapies, contraindicated agent combinations, and when and how to treat.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Apply efficacy and safety data to treatment decisions for optimal management of HCV.
intended audience
US and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care
Commercial supporters
Supported by an educational grant from Gilead Sciences, Inc.
Max credits:
- 0.50 / AMA PRA Category 1 Credit(s)
- 0.50 / AMA PRA Category 1 Credit(s) / ABIM MOC Point(s)
- 0.50 / AAPA Category 1 CME Credits
- 0.50 / ANCC Contact Hour(s)
- 0.50 / CE for Pharmacists
expires: May 17, 2023
These Infectious Disease CME/CE courses, powered by myCME, are specialty-based courses, resources, and news tailored and curated for you. Specialized topics include these and more:
Make sure to take advantage of these accredited free Infectious Disease CE and CME courses for your continuing education.
